Regulatory Spotlight: Morepen Labs Confronts ₹1.18B GST Show Cause Notice

Morepen Laboratories Ltd has received a ₹1.18 billion GST show cause notice over alleged tax discrepancies. The company is reviewing the matter and plans to respond appropriately. The notice highlights increasing regulatory scrutiny in India’s pharmaceutical sector, raising short-term investor concerns while emphasizing the need for stronger compliance frameworks.

Show more

Stay Ahead – Explore Now! Rajesh Power Services Ltd Secures Major Turnkey Contract Valued At ₹1.83 Billion From MGVCL